logo
#

Latest news with #ToshibaESS

M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy
M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy

Zawya

time28-05-2025

  • Business
  • Zawya

M42, Cleveland Clinic Abu Dhabi, Gunma University in Japan to drive innovation in heavy ion therapy

ABU DHABI - M42 and Cleveland Clinic Abu Dhabi, have signed a Memorandum of Cooperation (MoC) with Gunma University in Japan to accelerate research and innovation in heavy ion therapy, one of the most advanced and precise forms of radiation therapy for cancer treatment. This collaboration, which took place during M42 and Cleveland Clinic Abu Dhabi's recent delegation visit to Japan, will see the three entities exchange knowledge, expertise and research to deepen scientific understanding and broaden the clinical applications of heavy ion therapy. The collaboration builds on M42 and Cleveland Clinic Abu Dhabi's recent partnership with Toshiba Energy Systems & Solutions Corporation (Toshiba ESS) to establish the region's first heavy ion therapy facility in Abu Dhabi. This initiative will introduce one of the world's most innovative cancer treatment technologies to the Middle East, positioning Abu Dhabi as a centre of excellence in oncology and precision medicine. With no heavy ion therapy centre within a five-hour flight of the UAE, the upcoming facility—strategically located on the Cleveland Clinic Abu Dhabi campus, adjacent to the Fatima bint Mubarak Centre, the region's first-of-its-kind comprehensive cancer centre—will enhance access to this treatment for patients across the Middle East. Dr. Georges-Pascal Haber, Chief Executive Officer of Cleveland Clinic Abu Dhabi, said, 'At Cleveland Clinic Abu Dhabi, our vision is to bring the most advanced, evidence-based treatments to our patients, and this partnership with Gunma University exemplifies that commitment. By combining our clinical expertise with Gunma's decades of leadership in heavy ion therapy, we are not only advancing scientific knowledge but also laying the groundwork for a new era of cancer care in the region." President Ishizaki Yasuki at Gunma University, commented, 'Gunma University has long been committed to advancing the science of heavy ion therapy through rigorous research and clinical innovation." He added, "Partnering with M42 will enable us to expand the reach of this transformative therapy, fostering international collaboration and ensuring that more patients worldwide benefit from the latest advancements in cancer treatment.' Gunma University has been at the forefront of radiation oncology and nuclear medicine in Japan for decades. The Gunma University Heavy Ion Medical Centre (GHMC), established in 2005, has been instrumental in refining heavy ion radiotherapy by integrating radiation biology, clinical studies, and cutting-edge treatment technologies.

M42 and Cleveland Clinic Abu Dhabi partners with Toshiba Energy Systems & Solutions Corporation to build Middle East's first heavy-ion therapy facility for cancer treatment in Abu Dhabi
M42 and Cleveland Clinic Abu Dhabi partners with Toshiba Energy Systems & Solutions Corporation to build Middle East's first heavy-ion therapy facility for cancer treatment in Abu Dhabi

Al Etihad

time15-04-2025

  • Health
  • Al Etihad

M42 and Cleveland Clinic Abu Dhabi partners with Toshiba Energy Systems & Solutions Corporation to build Middle East's first heavy-ion therapy facility for cancer treatment in Abu Dhabi

15 Apr 2025 12:27 ABU DHABI (ALETIHAD)M42 is set to build a heavy ion therapy facility at Cleveland Clinic Abu Dhabi, bringing one of the most advanced and effective cancer treatment technologies to the Middle East and positioning Abu Dhabi as a global leader in oncology innovation and care. The announcement was made during Abu Dhabi Global Health Week (ADGHW) 2025, a major government initiative by the Department of Health – Abu Dhabi (DoH) that seeks to advance the future of health and no heavy ion therapy centre within a five-hour flight radius of the UAE, this facility ensures patients from across the region can access world-class care. The advanced form of radiation therapy will deliver unparalleled precision in targeting and destroying cancerous tumours with greater efficacy, revolutionising cancer treatment, and filling a critical gap in advanced care options for patients in the UAE and the broader of the new facility will begin in 2026 at the Cleveland Clinic Abu Dhabi (CCAD) campus, adjacent to the recently launched Fatima bint Mubarak Center, a first-of-its-kind cancer centre that delivers a multidisciplinary approach to cancer care. The heavy-ion therapy system will include one treatment room equipped with a rotating gantry and one horizontally fixed beam treatment room. The system incorporates cutting-edge high-speed scanning irradiation technology, and a compact rotating gantry equipped with superconducting with the Fatima bint Mubarak Center, the state-of-the-art facility further underscores CCAD's position as a leader in oncology advancements and personalised care, offering a comprehensive and multidisciplinary approach to cancer treatment, under one first heavy ion therapy system in the region follows a strategic partnership between M42 and Toshiba Energy Systems & Solutions Corporation (Toshiba ESS). The collaboration combines M42's expertise in healthcare innovation with Toshiba ESS's technological advancements in particle therapy, positioning Abu Dhabi as a hub for cutting-edge cancer agreement was recently signed in the UAE by Hasan Jasem Al Nowais, Managing Director and Group Chief Executive Officer of M42, and Chairman of CCAD, alongside Tsutomu Takeuchi, Director, Vice President for Power Systems Division, and Chief Nuclear Officer of Toshiba ESS, marking a significant milestone in the region's healthcare Nowais said, "M42's partnership with Toshiba ESS is a significant step that reinforces our commitment to reshaping the future of global health through cutting-edge innovations and technologies. By introducing heavy ion therapy to the Middle East, we are not only enhancing Cleveland Clinic Abu Dhabi's oncology capabilities but also plugging in a critical gap in cancer treatment options for people in the region. With no other heavy ion radiotherapy center within a five-hour flight radius of Abu Dhabi, this advanced, accurate and effective form of radiation therapy gives hope to cancer sufferers in the region."Takeuchi said, 'Toshiba has always been at the forefront of technological innovation for societal benefit. We are thrilled to partner with M42 to transform cancer treatment in the Middle East region. Heavy ion therapy represents a significant leap forward in radiation therapy, offering faster and less frequent treatments. We look forward to seeing the positive impact this technology will have on cancer patients' lives.'Chief Executive Officer of CCAD, Dr Georges-Pascal Haber, said, "At Cleveland Clinic Abu Dhabi, we are dedicated to bringing the world's most advanced cancer treatment modalities to our patients. The introduction of heavy ion therapy is a testament to our relentless pursuit of innovation and excellence in oncology. By integrating this cutting-edge technology into our cancer care programme, we are not only enhancing treatment outcomes but also providing hope to patients across the globe facing some of the most challenging cancer diagnoses. This milestone solidifies our position as a global leader in personalised, patient-centered oncology care."Heavy ion therapy is globally acclaimed for its superior physical and radiobiological properties compared to traditional photon-based therapies. The advanced treatment delivers higher doses of radiation directly to tumours while minimising damage to surrounding healthy benefits include shorter, less frequent treatment sessions, significantly reducing the overall burden on patients. For instance, early-stage lung cancer can be treated in a single outpatient heavy ion therapy is particularly effective for treating tumours that are inoperable or resistant to conventional therapies, including large tumours and liver metastases. Moreover, it lowers the risk of secondary cancers, offering patients a more effective initial treatment and a safer long-term only 15 centres worldwide offering heavy ion radiotherapy, the addition of this therapy to the Fatima bint Mubarak Center will position the region at the forefront of global oncology services. The development ensures the most advanced radiation therapy is available to patients in the UAE and beyond, marking a significant milestone in cancer treatment innovation.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store